1,340 results on '"Gentile, Massimo"'
Search Results
2. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study
3. Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients
4. Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity
5. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
6. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
7. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
8. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
9. Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate–high-risk patients: a systematic review and meta-analysis
10. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia
11. Momelotinib in myelofibrosis
12. MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells
13. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
14. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
15. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.
16. An Update on the Entomology, Virology, Pathogenesis, and Epidemiology Status of West Nile and Dengue Viruses in Europe (2018–2023).
17. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
18. Selinexor in multiple myeloma
19. Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients
20. Editorial: Covid-19 therapies in patients with hematologic malignancies
21. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
22. Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies
23. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort
24. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety
25. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
26. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
27. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
28. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis.
29. Editorial: Lymphoid cells and tumor microenvironment: a functional crosstalk
30. Ivosidenib in acute myeloid leukemia
31. Teclistamab‐cqyv in multiple myeloma
32. Tagraxofusp in myeloid malignancies
33. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
34. Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi
35. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
36. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
37. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
38. Differential interferon gene expression in bronchiolitis caused by respiratory syncytial virus-A genotype ON1
39. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts
40. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
41. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study
42. Teclistamab‐cqyv in multiple myeloma.
43. The Epidemiology of Anal Human Papillomavirus (HPV) in HIV-Positive and HIV-Negative Women and Men: A Ten-Year Retrospective Observational Study in Rome (Italy).
44. Tagraxofusp in myeloid malignancies.
45. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
46. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
47. Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
48. P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
49. PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
50. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.